You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 9, 2026

Indonesia’s Updated Regulation on Food Packaging

Subscribe to Updates

On June 30, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 11 of 2026 on Food Packaging, which expands the list of approved food-contact substances and recognizes a broader range of permissible functions for those substances. The new regulation, which revokes BPOM Regulation No. 20 of 2019, reflects developments in packaging technology and materials science.

Although the new regulation provides more advantages to business actors by adding more food contact substances to the approved list for use in food packaging, there are more stringent rules and restrictions for testing. One of the most significant changes is a comprehensive migration-testing framework that sets out requirements for packaging materials, testing conditions, food simulants, and specific migration limits.

Overall and Specific Migration

Under BPOM Regulation No. 20 of 2019, migration requirements were primarily set out within the lists of approved food-contact substances and packaging materials. BPOM Regulation No. 11 of 2026 instead expressly requires packaging materials that come into direct contact with food to meet both overall and specific migration limits. These are defined as follows:

  • Overall migration: The total quantity of all substances that migrate from the packaging, regardless of whether the substances are hazardous or nonhazardous to health.
  • Specific migration: The quantity of a particular identified substance known to be hazardous to health that migrates from the packaging.

Stricter Limits on Heavy Metals

The overall migration limit for plastic packaging remains unchanged under both regulations at 60 mg/kg or 10 mg/dm². However, the new regulation introduces significant changes to the regulation of heavy metals. Under the 2019 regulation, four heavy metals—lead, cadmium, chromium VI, and mercury—were subject to a single combined limit of 1 mg/kg. The 2026 regulation, however, requires each heavy metal to meet its own individual specific migration limit, adds arsenic as a newly regulated substance, and broadens the scope of chromium testing from chromium VI (Cr(VI)) to total chromium (Cr). The specific migration limits under the 2026 Regulation are set out below:

  • Arsenic (As): Not detected (LOD 0.01 mg/kg)
  • Cadmium (Cd): Not detected (LOD 0.002 mg/kg)
  • Total Chromium (Cr): Not detected (LOD 0.01 mg/kg)
  • Lead (Pb): 0.05 mg/kg
  • Mercury (Hg): Not detected (LOD 0.01 mg/kg)

Updated Rules on Food Simulants

A food simulant is a medium used to mimic the characteristics of a particular food to simulate the migration of components from the food packaging into the food. The 2026 regulation identifies five types of food simulants for use in overall migration testing, as follows:

  • Simulant A: Ethanol 10% (v/v)
  • Simulant B: Acetic acid 3% (w/v)
  • Simulant C: Ethanol 20% (v/v)
  • Simulant D1: Ethanol 50% (v/v)
  • Simulant D2: Vegetable oil containing less than 1% unsaponifiable matter; if food simulant D2 cannot be used, 95% alcohol or isooctane may be used as an alternative food simulant
  • Simulant E: Poly (2,6-diphenyl-p-phenylene oxide), particle size 60–80 mesh, pore size 200 nm

Under the 2019 regulation, simulant D2 was defined as vegetable oil, with no specific compositional requirements. The 2026 regulation narrows this definition and provides an alternative for situations where simulant D2 cannot be used.

New Requirements for Food Product Composition

The 2026 regulation introduces new disclosure requirements for the composition of food products that may come into contact with their packaging material. The name, percentage, and function of each component must be declared, and the sum of all declared percentages must equal 100%.

New Testing Requirements for Reusable Plastic Packaging

The 2026 regulation introduces additional requirements for reusable food packaging. Reusable plastic packaging must meet both the overall and specific migration limits through the testing protocol prescribed in Annex V.

For overall migration, compliance may be demonstrated in a single test. If the first result meets the applicable limit, no further testing is required. If it does not, up to two additional tests are permitted, provided that the results show a decreasing trend, with the second result lower than the first, and the third lower than the second.

Specific migration, by contrast, requires three tests in order to simulate the repeated contact that occurs over the packaging’s service life. Each result must meet the applicable specific migration limit, and the levels must not increase across the cycles; the second result may not exceed the first, and the third may not exceed the second. Compliance depends on these results, as well as on the stability of the packaging material throughout the three testing cycles. A material is considered unstable if detectable migration increases from the first test to the third, even when the migration values remain below the applicable regulatory limit.

Because contact under single-use conditions represents the worst-case scenario for migration, test data generated under those conditions is generally understood to support compliance for repeated-use applications as well.

Transition Period

BPOM Regulation No. 11 of 2026 provides a 12-month transition period from its promulgation date to allow food packaging products already circulating in the market to comply with the new requirements. Food packaging that was already in circulation before the regulation entered into force must be brought into compliance with the new regulation by June 30, 2027.

Business Impact

BPOM Regulation No. 11 of 2026 updates Indonesia’s food packing rules to better respond to developments in food packaging technology and materials science. Food packaging manufacturers, importers, and brand owners in Indonesia should review existing compliance practices and test reports to confirm that packaging intended for direct food contact meets the new overall and specific migration requirements.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 24, 2024
Thailand’s Minister of Public Health recently promulgated the Ministerial Notification Re: Category 5 Narcotics Which Are Not Cannabis or Hemp Extract and Whose Consumption is Permitted for Treatment of Disease or for Research Purposes (2024). The notification took effect on April 23, 2024. The substances whose regulatory controls are affected by this new notification are psilocybin mushroom (Psilocybe cubensis (Earle) Singer), opium poppy (Papaver somniferum L. and Papaver bracteatum Lindl.), and other plants in these genera from which opium, opium alkaloids, psilocybin, or psilocin may be derived. As a result of this notification, these substances are now classified as category 5 narcotics that can be applied in medical treatment. Without the implementation of this notification, patients could not access newly developed medicines containing these substances, as Thailand’s Narcotic Code prohibits the possession and use of category 5 narcotics. Nonetheless, this does not mean that psilocybin mushrooms and opium can be used without any conditions. There is still a long process to go through before these substances can be used in medical treatment or clinical studies. Under the new notification, the FDA must first approve any medicinal drug formulation containing any of the above substances, and subsequently, the production must be approved for medical use or research purposes. The importation of medicinal drug formulations containing psilocybin mushrooms or opium is not allowed. This seemingly small regulatory change addresses the previous legal obstacle to the research and development of such medicines. According to the previous regulation, a physician or researcher could apply to the Thai FDA for a license to produce or possess medicines containing the aforementioned narcotics. However, production and consumption are considered different activities, and consuming a narcotic-containing medicine, even if it was produced under a valid license, is prohibited by the Narcotics Code and is punishable by imprisonment,
Read More
June 11, 2024
Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops. Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms. Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another. GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants. In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU
Read More
February 14, 2024
Thailand is preparing to implement new rules on drug importation for clinical studies. The Medicines Regulation Department of Thailand’s Food and Drug Administration (Thai FDA) first issued the Notification Re. Detailed Requirements for Drug Importation into Thailand for Clinical Studies almost a year ago, and the notification is expected to come into effect on March 1, 2024. Key Provisions The notification aims at enhancing the efficiency of conducting clinical studies while ensuring the protection of human subjects participating in such studies within Thailand. Some of its key provisions include: Definition of Clinical Study. The notification defines a “clinical study” as a study of a medicine involving human subjects, conducted to provide supporting evidence for the registration of a medicinal product in Thailand or other countries, including for additional indications or variations of a registration dossier. Compliance with ICH GCP. Clinical studies conducted in Thailand must adhere to the current edition of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) guidelines. Clinical Trial Application. Sponsors are required to submit a clinical trial application along with supporting documents to the Thai FDA for approval before commencing a clinical study. The permit remains valid for five years and is renewable. Supply of Investigational Drugs. Sponsors must obtain investigational drugs from manufacturers compliant with Good Manufacturing Practice (GMP) standards as recognized by the Thai FDA. Postapproval Obligations. The secretary-general of the Thai FDA may impose postapproval conditions or order investigators to conduct or suspend certain activities to ensure human subject protection and regulatory compliance. Regulatory Oversight. The Thai FDA is responsible for inspecting and overseeing the regulatory compliance of clinical studies, including during prestudy, ongoing, and poststudy phases. The Thai FDA may also conduct inspections of clinical studies conducted overseas. The Thai FDA
Read More
December 15, 2023
As part of its membership in Lex Mundi, Tilleke & Gibbins has published an updated edition of its Guide to Doing Business in Thailand for 2023. This guide outlines the key factors for starting and operating a business in the Thai market. Issues covered include: Investment incentives Financial facilities Exchange controls Import and export regulations Structures for doing business Requirements for the Establishment of a Business Operation of the Business Cessation or Termination of the Business Labor legislation, relations, and supply Tax Immigration requirements This publication is part of Lex Mundi’s Country Guides series prepared by member firms in more than 100 jurisdictions worldwide. The guides serve as a useful resource for planning international business strategy and researching new markets. The full Guide to Doing Business in Thailand is available through the button below.
Read More